FDA Opens Door to Wider Avandia Prescribing

(MedPage Today) -- The FDA has loosened restrictions on the diabetes drug rosiglitazone (Avandia) -- under fire since 2007 because of potential cardiovascular risks -- and will allow drugmaker GlaxoSmithKline to drop a postmarketing study of the drug.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news